Shares of Karyopharm Therapeutics (NASDAQ:KPTI) reached a new 52-week high and low during trading on Wednesday . The company traded as low as $18.88 and last traded at $18.64, with a volume of 24742 shares. The stock had previously closed at $18.46.
A number of analysts recently commented on the stock. ValuEngine raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, February 8th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday. BidaskClub raised shares of Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. Finally, Canaccord Genuity boosted their price objective on shares of Karyopharm Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, March 12th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $21.10.
The stock has a market capitalization of $924.22 million, a PE ratio of -6.79 and a beta of 3.62.
In other Karyopharm Therapeutics news, EVP Christopher Brett Primiano sold 2,000 shares of Karyopharm Therapeutics stock in a transaction dated Thursday, May 10th. The shares were sold at an average price of $18.01, for a total transaction of $36,020.00. Following the completion of the transaction, the executive vice president now owns 675 shares in the company, valued at $12,156.75. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock in a transaction dated Monday, April 9th. The stock was sold at an average price of $12.48, for a total transaction of $124,800.00. Following the transaction, the insider now owns 723,510 shares of the company’s stock, valued at approximately $9,029,404.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 67,000 shares of company stock valued at $1,021,320. 14.71% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in KPTI. Teacher Retirement System of Texas acquired a new position in Karyopharm Therapeutics during the fourth quarter worth about $115,000. MetLife Investment Advisors LLC acquired a new position in Karyopharm Therapeutics during the fourth quarter worth about $146,000. Two Sigma Investments LP raised its position in Karyopharm Therapeutics by 76.8% during the fourth quarter. Two Sigma Investments LP now owns 24,220 shares of the company’s stock worth $233,000 after acquiring an additional 10,520 shares during the last quarter. UBS Group AG raised its position in Karyopharm Therapeutics by 761.8% during the first quarter. UBS Group AG now owns 19,632 shares of the company’s stock worth $264,000 after acquiring an additional 17,354 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in Karyopharm Therapeutics during the first quarter worth about $269,000. Institutional investors own 62.65% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.